BioRestorative Therapies (BRTX) EBT Margin (2012 - 2025)
BioRestorative Therapies' (BRTX) quarterly EBT Margin came in at 134741.33% in Q4 2025, down 12842861.0% YoY from N/an in Q4 2024, and down 328.67% on a QoQ basis from 31432.3% in Q3 2025.
BioRestorative Therapies (BRTX) EBT Margin (2012 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 14 years of EBT Margin data on file, last reported at 134741.33% in Q4 2025.
- Quarterly EBT Margin fell 12842861.0% year-over-year to 134741.33% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 10888.81% (down 796311.0% YoY) and the FY2025 annual result came in at 10628.62%, down 40685.0% from the prior year.
- EBT Margin declined to 134741.33% in Q4 2025, from 31432.3% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 979.39% in Q3 2024 to a low of 134741.33% in Q4 2025.
- A 5-year average of 34423.09% and a median of 17751.45% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin soared 11073506 bps — and 2025, when it slumped 12842861 bps.
- Tracing BRTX's EBT Margin over 5 years: stood at 80977.2% in 2021, then tumbled by 58 bps to 127640.19% in 2022, then jumped by 87 bps to 16905.12% in 2023, then surged by 63 bps to 6312.72% in 2024, then sank by 2034 bps to 134741.33% in 2025.
- The last three EBT Margin figures came in at 134741.33% (Q4 2025), 31432.3% (Q3 2025), and 1211.71% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | -19,516.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -134,741.33% |
| Sep 30, 2025 | -31,432.30% |
| Jun 30, 2025 | -1,211.71% |
| Mar 31, 2025 | -21,494.49% |
| Dec 31, 2024 | -6,312.72% |
| Sep 30, 2024 | -979.39% |
| Jun 30, 2024 | -2,774.14% |
| Mar 31, 2024 | -12,111.56% |
| Dec 31, 2023 | -16,905.12% |
| Sep 30, 2023 | -10,165.43% |
| Jun 30, 2023 | -4,867.54% |
| Mar 31, 2023 | -18,597.78% |
| Dec 31, 2022 | -127,640.19% |
| Sep 30, 2022 | -16,064.88% |
| Jun 30, 2022 | -6,594.00% |
| Mar 31, 2022 | -31,841.10% |
| Dec 31, 2021 | -80,977.20% |
| Sep 30, 2021 | -52,302.90% |
| Jun 30, 2021 | -27,591.13% |
| Mar 31, 2021 | -83,856.94% |